Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss ⊖
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
2026 › February › 24
CagriSema
4 months ago
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades ⊖
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
page 1 of 1